Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment‐experienced individual | Zendy

Johnson S. W. | Zendy; Davis M. M. | Zendy; Stever L. M. | Zendy; Priest D. H. | Zendy

Premium

Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment‐experienced individual

Author(s) -

Johnson S. W.,

Davis M. M.,

Stever L. M.,

Priest D. H.

Publication year - 2016

Publication title -

journal of clinical pharmacy and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 73

eISSN - 1365-2710

pISSN - 0269-4727

DOI - 10.1111/jcpt.12455

Subject(s) - sofosbuvir , ledipasvir , simeprevir , medicine , hepatitis c virus , virology , hepatitis c , chronic hepatitis , virus , ribavirin

Summary What is known and objective Significant progression in the treatment of chronic hepatitis C virus has been made with the introduction of direct‐acting antivirals ( DAA s). However, limited data are available for the retreatment of individuals who have failed multiple prior DAA s. Case description We report a single case of an individual who was unsuccessfully treated with five prior hepatitis C virus treatment regimens including simeprevir plus sofosbuvir who was successfully cured after treatment with ledipasvir/sofosbuvir. What is new and conclusion Ledipasvir/sofosbuvir may be an option for treating patients who have failed multiple prior DAA regimens; however, further research is warranted.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research